Tetraneuron will receive 1M€ from the IVF and FEDER to advance its therapy against Alzheimer’s Disease
With this new line of funding, Tetraneuron will advance both in the preclinical development of his gene therapy for Alzheimer’s disease and opening a new line of research around glaucoma. E2F4-based gene therapy can mitigate the main molecular, cognitive, and behavioral alterations related to Alzheimer’s disease through a multifactorial…
-
With this new line of funding, Tetraneuron will advance both in the preclinical development of his gene therapy for Alzheimer’s disease and opening a new line of research around glaucoma.
-
E2F4-based gene therapy can mitigate the main molecular, cognitive, and behavioral alterations related to Alzheimer’s disease through a multifactorial approach.
27th December 2021.- Tetraneuron, a company developing a multifactorial gene therapy for the treatment of Alzheimer’s disease (AD) and other neurodegenerative diseases will receive 1M€ of financing through the line of disruptive project loans, co-financed by the Valencian Institute of Finance (www.ivf.gva.es/) and FEDER.
Based on gene therapy, his project has been one of the six approved by multiple requests. During its evaluation, the Valencian Institute of Finance has especially valued both the novelty and the high dose of innovation implied by the Tetraneuron proposal for managing diseases as complex as Alzheimer’s disease.
With this new line of funding, Tetraneuron will advance both in the preclinical development of his gene therapy for Alzheimer’s disease and opening a new line of research around glaucoma.
Regarding the candidate TET-E2F4DN as a therapy for AD, the company expects to obtain FDA approval for its preclinical roadmap and the related clinical design.
About Tetraneuron
The first Spanish biotech company accelerated by the Johnson & Johnson European Innovation Center, Tetraneuron (www.tetraneuron.com), is developing an advanced therapy for Alzheimer’s disease through a therapeutic approach focused on E2F4, a protein involved in the origin of the pathogenesis mechanism of this complicated disease.
With encouraging in vivo preclinical results in an AD mouse model with an aggravated phenotype, the company is managing a multifactorial approach to Alzheimer’s Disease throughout his gene therapy, intending to top this devastating disease that affects more than 50 million people worldwide. Unlike other strategies, Tetraneuron provides a disruptive vision addressing the global causes of the pathology from its inception.
The advance of gene therapy regulation is evident in recent success stories and opens a new horizon to those diseases without adequate treatment. In that sense, Tetraneuron is also taking its vision to develop innovative products in other neurodegenerative disorders.
For more information,
Mari Carmen Álvarez (mc.alvarez@tetraneuron.com)
David Mor (david.mor@grupoifedes.com)